$RYTM News

Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine

Rhythm Pharmaceuticals Announces Publication Of An Evidence-Based, Consensus-Driven Diagnostic Algorithm For Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rhythm Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $137

Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $144

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates

Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call

How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE Expansion

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

Rhythm Pharmaceuticals Presents New Data At The Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythmn Pharmaceuticals Announces European Commission Expansion Of The Marketing Authorization For Imcivree For Obesity And Control Of Hunger In Adults And Children 4 Years Of Age And Above With Acquired Hypothalamic Obesity

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for

Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines

Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now?